Compare Live Nation Entertainment, Inc. (LYV) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Live Nation Entertainment, Inc. vs Sanofi SA — how do they compare? Live Nation Entertainment, Inc. trades at $173.76 (market cap $39.92B), while Sanofi SA trades at $40.02 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 2.4× Live Nation Entertainment, Inc.'s market cap, and Sanofi SA pays a 6.01% dividend while Live Nation Entertainment, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Live Nation Entertainment, Inc. for 72 Days and Sanofi SA for 94 Days on average.
| LYV | SNY | |
|---|---|---|
Market Cap | $39.92B | $95.18B |
Volume | 1,982,609 | 2,995,646 |
Sector | Media | Health |
52-Week High | $188.46 | $52.34 |
52-Week Low | $125.61 | $39.51 |
Typical Hold Time | 72 Days | 94 Days |
Enterprise Value | $42.13B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Live Nation Entertainment (LYV) trades at $170.84, down 0.55% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 earnings beat with 1.05 EPS versus 0.66 expected, though Q1 and Q4 2025 missed estimates. Revenue growth continues with $25.2B in 2025, while net income margin remains thin at 0.51%. Analyst consensus is strongly bullish with 87% buy ratings and a $208.18 price target, representing 22% upside potential.
LYV benefits from strong consumer demand for live events ('funflation' trend) and record deferred revenue of $6.4B, but faces execution risks from cost pressures, legal uncertainties, and high debt levels. The stock's elevated P/E of 117.5 reflects growth expectations, making it sensitive to earnings delivery. Near-term support sits at $169 with resistance at $172.
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
